There are many roads to the huge “gold mountain” of international high-end market; however, not every road is smooth. Numerous pharmaceutical enterprises are now exploring which road to enable them to climb the mountain first. Zhang Tao said that, “There is no shortcut in international certification, but only is way that better suits the enterprise. No matter whether the U.S. FDA certification, Europe GMP certification or WHO PQ certification, the requirements are strict”.
According to information, the relatively popular practice in China is to sell products to foreign countries via international procurement organizations, which is much easier compared to direct sales for occupying foreign markets; and has higher rate of return compared to manufacturing consignment. Beiyuan Branch of North China Pharmaceutical has tasted the sweetness therein since exploiting international markets in 2010.
An Guohong, the Deputy Chief Engineer of North China Pharmaceutical who has been trained in an Europe transnational corporation, said with deep feelings regarding how enterprises to walk on their future roads, “What the large transnational corporations in the globe pursue in the aspect of pharmaceutical product quality is to make quality products, especially for sterile products: they invest their quality assurance capacity at all costs, which is a very good enlightenment for Chinese pharmaceutical enterprises.
It will be our inevitable choice to walk on the road of strengthening quality and establish self-owned brand in the international market.” The streptomycin sulfate for injection of new preparation branch of North China Pharmaceutical that has just been conducted on-site inspection of PQ certification will be the first self-owned brand preparation product of North China Pharmaceutical to enter international high-end market, which is estimated to create benefit of over 20 million yuan every year. North China Pharmaceutical has screened a batch of similar varieties which will be successively exploited international market in the future.
